Bill Summary

H.F. 4504

As introduced

Subject	Prescription drug price transparency
Authors	Morrison
Analyst	Randall Chun
Date	March 23, 2022

Overview

Minnesota Statutes, section 62J.84, requires drug manufacturers to report specified information to the commissioner of health for: prescription drugs for which the price, and price increases, exceed specified thresholds; new prescription drugs that exceed a price threshold; and newly acquired prescription drugs for which the price, and price increases, exceed specified thresholds. The commissioner is required to post this information on the department's website. This bill modifies and clarifies these reporting requirements for drug manufacturers.

Summary

Section	Description
1	**Prescription drug price transparency.** Amends § 62J.84. The amendment to subdivision 2 adds definitions of: course of treatment, National Drug Code, and 30-day supply. The amendment to subdivision 3 modifies reporting requirements for prescription drugs for which the price was $100 or greater for a 30-day supply or course of treatment lasting less than 30 days, and for which the increase in price exceeds specified thresholds, by: ▪ requiring reporting for biosimilar drugs with a price increase of 50 percent or more; ▪ requiring the manufacturer to provide a description of the drug, and to list the following information separately: National Drug Code, product name, dosage form, strength, and package size; ▪ clarifying the meaning of introductory price and requiring reporting of the price of the drug on the last day of each of the five calendar years preceding the price increase;

Section **Description**

- requiring direct costs incurred and financial assistance provided to be reported for the previous 12-month period;
- clarifying the reporting of the ten highest prices in other countries; and
- requiring specified information to be reported if the drug was acquired by the manufacturer during the previous 12-month period.

The amendment to subdivision 4 modifies reporting requirements for new prescription drugs with prices that exceed specified thresholds, by:

- clarifying that the tier price threshold also applies to a course of treatment lasting less than 30 days; and
- requiring the manufacturer to provide a description of the drug, and to list the following information separately: National Drug Code, product name, dosage form, strength, and package size.

The amendment to subdivision 5 modifies reporting requirements for newly acquired prescription drugs for which the price and price increases exceed specified thresholds, by:

- requiring the manufacturer to provide a description of the drug, and to list the following information separately: National Drug Code, product name, dosage form, strength, and package size.